PPD picks up Bioclinica’s global site business

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)

Related tags: Ppd, AES, Patient recruitment, Clinical trial sites

The acquisition of Bioclinica’s clinical research site business extends PPD’s trial enrollment business to five continents, 20 countries, and more than 180 research sites.

PPD’s ​Accelerated Enrollment Solutions (AES) business unit today acquired the clinical research site business of Bioclinica.

“This acquisition further strengthens our ability to rapidly recruit patients and seamlessly execute trials,”​ Roger Smith, senior vice president and general manager of Accelerated Enrollment Solutions (AES), told us, adding that the company’s goal is to have the resources on hand to deliver larger, more diverse client projects.

Smith called the acquisition ‘an important step’ toward meeting this goal, as it adds new sites and ‘opens key markets’ for AES in China, Latin America, and Western Europe.

The deal also bolsters the company’s presence in North America, Europe, and South Africa, and provides dedicated research sites in Florida with ‘significant’ neuroscience expertise. Of the four FL-based sites, one is dedicated to Phase I trials and will move to PPD’s early development team.

“Bringing these new sites on board under AES strengthens our ability to execute, manage, and budget our clients’ trials with greater precision and advances our strategy of becoming the world’s largest patient access and site conduct organization,”​ added Smith. The new sites also present opportunities to grow the business in new therapeutic areas.

“We also will continue to enhance variations of the core services we can support with these sites to meet the specific needs of our clients, particularly at the indication level … and based on geographic considerations,”​ Smith said.

Financial details were not disclosed.

Related news

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars